Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis

• Główni autorzy: Francisco Cezar Aquino de Moraes (Autor), Caroline R. M. Pereira (Autor), Vitor Kendi Tsuchiya Sano (Autor), Estella Aparecida De Laia (Autor), Carlos Stecca (Autor), Rommel Mario Rodríguez Burbano (Autor)
• Format: Książka
• Wydane: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Background:The CDK 4/6 inhibitors, including palbociclib and ribociclib, are the standard first-line treatment for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Proton pump inhibitors are one of the most globally prescribed ty...